Tyra Biosciences posts Q3 results with $274.9 million in cash and equivalents

Reuters11-06

<a href="https://laohu8.com/S/TYRA">Tyra Biosciences</a> posts Q3 results with $274.9 million in cash and equivalents

Tyra Biosciences Inc. reported a net loss of $29.9 million for the third quarter ended September 30, 2025, compared to a net loss of $24.0 million for the same period in 2024. Research and development expenses were $25.5 million, up from $22.7 million in the previous year, primarily due to start-up and enrollment activities in the BEACH301, SURF302, and SURF431 studies. General and administrative expenses increased to $7.5 million from $5.9 million, mainly driven by higher personnel-related costs, including non-cash stock-based compensation. The company held $274.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and expects this to fund operations through at least 2027. During the quarter, Tyra dosed the first patients with dabogratinib in the BEACH301 and SURF302 trials and expanded its development into low-grade upper tract urothelial carcinoma following FDA clearance. Interim results from ongoing studies are expected in 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16125) on November 05, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581370164?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 05:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581370164","market":"fut","top_or_hot":-1,"title":"Tyra Biosciences posts Q3 results with $274.9 million in cash and equivalents","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TYRA\">Tyra Biosciences</a> posts Q3 results with $274.9 million in cash and equivalents\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tyra Biosciences Inc. reported a net loss of $29.9 million for the third quarter ended September 30, 2025, compared to a net loss of $24.0 million for the same period in 2024. Research and development expenses were $25.5 million, up from $22.7 million in the previous year, primarily due to start-up and enrollment activities in the BEACH301, SURF302, and SURF431 studies. General and administrative expenses increased to $7.5 million from $5.9 million, mainly driven by higher personnel-related costs, including non-cash stock-based compensation. The company held $274.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and expects this to fund operations through at least 2027. During the quarter, Tyra dosed the first patients with dabogratinib in the BEACH301 and SURF302 trials and expanded its development into low-grade upper tract urothelial carcinoma following FDA clearance. Interim results from ongoing studies are expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16125) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tyra Biosciences posts Q3 results with $274.9 million in cash and equivalents</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTyra Biosciences posts Q3 results with $274.9 million in cash and equivalents\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 05:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TYRA\">Tyra Biosciences</a> posts Q3 results with $274.9 million in cash and equivalents\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tyra Biosciences Inc. reported a net loss of $29.9 million for the third quarter ended September 30, 2025, compared to a net loss of $24.0 million for the same period in 2024. Research and development expenses were $25.5 million, up from $22.7 million in the previous year, primarily due to start-up and enrollment activities in the BEACH301, SURF302, and SURF431 studies. General and administrative expenses increased to $7.5 million from $5.9 million, mainly driven by higher personnel-related costs, including non-cash stock-based compensation. The company held $274.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and expects this to fund operations through at least 2027. During the quarter, Tyra dosed the first patients with dabogratinib in the BEACH301 and SURF302 trials and expanded its development into low-grade upper tract urothelial carcinoma following FDA clearance. Interim results from ongoing studies are expected in 2026.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16125) on November 05, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TYRA","symbol_name":"Tyra Biosciences, Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nNDL1N4kl5:1","article_id":"2581370164","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581370164","pubTimestamp":1762376777,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tyra Biosciences Inc. reported a net loss of $29.9 million for the third quarter ended September 30, 2025, compared to a net loss of $24.0 million for the same period in 2024. Research and development expenses were $25.5 million, up from $22.7 million in the previous year, primarily due to start-up and enrollment activities in the BEACH301, SURF302, and SURF431 studies. General and administrative expenses increased to $7.5 million from $5.9 million, mainly driven by higher personnel-related costs, including non-cash stock-based compensation. The company held $274.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and expects this to fund operations through at least 2027. During the quarter, Tyra dosed the first patients with dabogratinib in the BEACH301 and SURF302 trials and expanded its development into low-grade upper tract urothelial carcinoma following FDA clearance. Interim results from ongoing studies are expected in 2026.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TYRA":"Tyra Biosciences, Inc.","BK4139":"生物科技"},"translate_title":"Tyra Biosciences公布第三季度业绩，现金及等价物为2.749亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TYRA":0.9},"content_text":"Tyra Biosciences posts Q3 results with $274.9 million in cash and equivalents\n    \n\n        Tyra Biosciences Inc. reported a net loss of $29.9 million for the third quarter ended September 30, 2025, compared to a net loss of $24.0 million for the same period in 2024. Research and development expenses were $25.5 million, up from $22.7 million in the previous year, primarily due to start-up and enrollment activities in the BEACH301, SURF302, and SURF431 studies. General and administrative expenses increased to $7.5 million from $5.9 million, mainly driven by higher personnel-related costs, including non-cash stock-based compensation. The company held $274.9 million in cash, cash equivalents, and marketable securities as of September 30, 2025, and expects this to fund operations through at least 2027. During the quarter, Tyra dosed the first patients with dabogratinib in the BEACH301 and SURF302 trials and expanded its development into low-grade upper tract urothelial carcinoma following FDA clearance. Interim results from ongoing studies are expected in 2026.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tyra Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA16125) on November 05, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581370164","isCrawlerRequest":true}